Research
Hormonal
Excessive fructose consumption promotes nonalcoholic fatty liver disease (NAFLD) by acting as both a substrate and an inducer of hepatic de novo lipogenesis (DNL), leading to lipid accumulation and subsequent oxidative stress and inflammation.
Limit intake of added fructose, particularly from sugar-sweetened beverages and processed foods, as it directly drives liver fat accumulation and inflammation. Focus on whole foods where fructose is accompanied by fiber.
GoodSupportsHIGH confidence
excessive fructose consumption is known to favor nonalcoholic fatty liver disease (NAFLD), as fructose is both a substrate and an inducer of hepatic de novo lipogenesis.
Why this rating
The paper is a review citing multiple human and animal studies, establishing strong mechanistic links and clinical associations.
Source
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Prasanthi Jegatheesan et al. · Nutrients · 2017
DOI 10.3390/nu9030230
narrative_reviewCited 274×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Fructose consumption promotes disease progression from simple steatosis to nonalcoholic steatohepatitis (NASH) by inducing oxidative stress, endoplasmic reticulum (ER) stress, and inflammation via mechanisms including uric acid production and methylglyoxal accumulation.Good
- Fructose consumption negatively impacts peripheral tissues (gut, muscle, adipose) through interorgan cross-talk, leading to gut dysbiosis, visceral adiposity, and muscle insulin resistance/sarcopenia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →